Product Highlight - Cruzor

30 Nov 2022
Product Highlight - Cruzor
KEEP BLOOD PRESSURE UNDER CONTROL WITH CRUZOR
• Good selectivity in diabetic nephropathy and cardiac disease
• Well tolerated treatment in hypertensive patient with type 2 diabetes and nephropathy
• Safety profile in long-term treatment
• Cost-effective
• Bioequivalent to the originator

References:
• Cruzor Tablet 300 mg Package Insert, May 2022.
• Cruzor (Irbesartan) Tablets 300 mg, BE fasting study.
• F. Gialama N. Maniadakis. Comprehensive overview: efficacy, tolerability, and cost effectiveness of irbesartan. 2013:9 575-592.
• V. Forni, G. Wuerzner, et al. Long-term use and tolerability of irbesartan for control of hypertension. 2011:4 17-26.

Related MIMS Drugs

Editor's Recommendations